CN110876766A - Application of peony seed oil in preparation of medicines and health-care foods for improving biomechanical properties of male bones - Google Patents
Application of peony seed oil in preparation of medicines and health-care foods for improving biomechanical properties of male bones Download PDFInfo
- Publication number
- CN110876766A CN110876766A CN201911245451.0A CN201911245451A CN110876766A CN 110876766 A CN110876766 A CN 110876766A CN 201911245451 A CN201911245451 A CN 201911245451A CN 110876766 A CN110876766 A CN 110876766A
- Authority
- CN
- China
- Prior art keywords
- seed oil
- peony seed
- soft capsule
- osteoporosis
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000736199 Paeonia Species 0.000 title claims abstract description 101
- 235000006484 Paeonia officinalis Nutrition 0.000 title claims abstract description 100
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims abstract description 98
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title claims description 24
- 235000013305 food Nutrition 0.000 title claims description 19
- 229940079593 drug Drugs 0.000 title claims description 17
- 239000007901 soft capsule Substances 0.000 claims abstract description 53
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 37
- 229940011871 estrogen Drugs 0.000 claims abstract description 24
- 239000000262 estrogen Substances 0.000 claims abstract description 24
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 18
- 239000011575 calcium Substances 0.000 claims abstract description 18
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 18
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 12
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 8
- 239000011710 vitamin D Substances 0.000 claims abstract description 8
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 8
- 229940046008 vitamin d Drugs 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000007902 hard capsule Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 235000013361 beverage Nutrition 0.000 claims abstract description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 30
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 239000011647 vitamin D3 Substances 0.000 claims description 13
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 239000000375 suspending agent Substances 0.000 claims description 8
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims description 7
- 229960000452 diethylstilbestrol Drugs 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 4
- 235000005282 vitamin D3 Nutrition 0.000 claims description 4
- 229940021056 vitamin d3 Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 48
- 230000002829 reductive effect Effects 0.000 abstract description 27
- 229960003604 testosterone Drugs 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 9
- 230000009467 reduction Effects 0.000 abstract description 8
- 229960005069 calcium Drugs 0.000 description 16
- 108091008039 hormone receptors Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 229960003563 calcium carbonate Drugs 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 229940088597 hormone Drugs 0.000 description 10
- 239000005556 hormone Substances 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 210000001550 testis Anatomy 0.000 description 10
- 206010017076 Fracture Diseases 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 9
- 208000010392 Bone Fractures Diseases 0.000 description 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000010603 microCT Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 230000002381 testicular Effects 0.000 description 6
- 206010065687 Bone loss Diseases 0.000 description 5
- 235000010216 calcium carbonate Nutrition 0.000 description 5
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 5
- 206010002261 Androgen deficiency Diseases 0.000 description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 229960004488 linolenic acid Drugs 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
- CHZJRGNDJLJLAW-RIQJQHKOSA-N (8r,9s,13s,14s,16r,17r)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-16,17-diol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 CHZJRGNDJLJLAW-RIQJQHKOSA-N 0.000 description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003262 anti-osteoporosis Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 3
- 239000001354 calcium citrate Substances 0.000 description 3
- 229960004256 calcium citrate Drugs 0.000 description 3
- 239000004227 calcium gluconate Substances 0.000 description 3
- 229960004494 calcium gluconate Drugs 0.000 description 3
- 235000013927 calcium gluconate Nutrition 0.000 description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229960003399 estrone Drugs 0.000 description 3
- 229960002568 ethinylestradiol Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229950007863 nilestriol Drugs 0.000 description 3
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013337 tricalcium citrate Nutrition 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 2
- 229960002535 alfacalcidol Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 239000011612 calcitriol Substances 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 201000011529 cardiovascular cancer Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001694 thigh bone Anatomy 0.000 description 2
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 2
- 229960001023 tibolone Drugs 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-CMDGGOBGSA-N (e)-octadec-10-enoic acid Chemical compound CCCCCCC\C=C\CCCCCCCCC(O)=O QXJSBBXBKPUZAA-CMDGGOBGSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000674717 Homo sapiens Transcription initiation factor TFIID subunit 7-like Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 102100021172 Transcription initiation factor TFIID subunit 7-like Human genes 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000011633 osteoporosis animal model Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000746 testosterone undecanoate Drugs 0.000 description 1
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
With the increase of age, the testosterone level of middle-aged and elderly men is gradually reduced, the biomechanical performance of bones is reduced, and the fracture and the osteoporosis are easy to occur; the invention provides a method for preparing peony seed oil into soft capsules, hard capsules, tablets, granules, oral liquids and beverages for clinical application, and the peony seed oil can be used for preventing and treating the population with the bone biomechanical property reduction caused by various reasons and the male osteoporosis patients. The invention also discloses formulas and preparation processes of the peony seed oil soft capsule, the peony seed oil vitamin D calcium agent soft capsule, the peony seed oil estrogen soft capsule and the peony seed oil aspirin soft capsule, and the products have good effects on preventing and treating low bone biomechanical function and osteoporosis of various crowds.
Description
Technical Field
The invention belongs to the technical field of health-care food and medicine production, and particularly relates to application of peony seed oil in preparation of medicines and health-care food for improving the biomechanical property of male bones.
Background
The study shows that the hormone metabolism of male bone is reduced, the hormone metabolism of male bone is increased, the hormone metabolism of male bone is reduced, the hormone metabolism of male bone, the hormone receptor of male bone is reduced, the hormone receptor of male bone, the hormone metabolism of male bone is reduced, the hormone receptor of male bone is reduced, the hormone metabolism of male bone, the hormone receptor of male bone, the hormone metabolism of male bone is reduced, the hormone receptor of male bone, the hormone metabolism of male bone, the hormone receptor of male bone is reduced, the hormone receptor of male bone is reduced, the hormone metabolism of male bone, the hormone receptor of male bone, the hormone metabolism of male bone is reduced, the hormone receptor of male bone is reduced, the hormone receptor of male bone, the hormone receptor of male bone is reduced, the hormone receptor of male bone is reduced, the hormone receptor, the rat is reduced, the rat is increased, the rat is reduced, the rat is increased, the rat is reduced, the rat is increased, the rat is the.
Peony (Paeonia suffruticosa Andr) belongs to deciduous shrubs of Paeonia of Ranunculaceae, is a unique and rare woody flower in China, peony seed oil contains a large amount of Unsaturated Fatty Acids (UFA) accounting for about 90% of total fatty acids, the unsaturated fatty acids mainly comprise stearic acid, palmitic acid, oleic acid, linoleic acid, isooleic acid, α -linolenic acid and the like, wherein α -linolenic acid content is 34% -74%, the peony seed oil contains the highest content of the UFA α -linolenic acid, has the functions of reducing blood sugar, reducing blood fat, losing weight, preventing cardiovascular diseases, resisting cancers and the like, is an indispensable nutrient substance for human bodies, and the American FDA confirms that α -linolenic acid has multiple functions of reducing blood fat and blood pressure, enhancing immunity, preventing diabetes, preventing and treating cancers, preventing cerebral apoplexy and myocardial infarction, clearing harmful substances in blood and UFA, relieving climacteric syndrome, refreshing, strengthening brain, enhancing attention and memory, assisting in treating multiple sclerosis, assisting in treating rheumatoid arthritis, resisting and preventing and treating skin and stomach diseases, and also has the function of rat, and the peony seed oil, and the rat, and the research of the osteoporosis, the rat, the male and the rat, the male.
Disclosure of Invention
In order to find a medicine capable of replacing testosterone and being used for male osteoporosis patients, a method for removing testicles is used for establishing an animal model of male osteoporosis caused by androgen deficiency, the influence of testosterone and peony seed oil on the reduction of the biomechanical performance of mouse bones caused by androgen deficiency and osteoporosis is observed, and the result shows that the peony seed oil has the obvious effect of improving the reduction of the biomechanical performance of the mouse bones without testicles and has good prevention effect on the loss of the bone mass and the osteoporosis of the mouse, and the effects are similar to the effect of testosterone (see example I).
According to the discovery, the peony seed oil provided by the invention can be added with a certain excipient to prepare clinically applicable soft capsules, hard capsules, tablets, oral liquid and granules, and the products can be used as medicines and health-care foods and used for preventing and treating people with bone biomechanical property reduction caused by various reasons and male osteoporosis patients. Since 2011 national ministry of health approves peony seed oil as a new resource food. The product prepared from the pure peony seed oil can also be used as a new resource food and is provided for people in need to take.
We also find that the peony seed oil can be added with calcium carbonate and vitamin D3 to form a group of health-care food suitable for all kinds of osteoporosis people, and the calcium supplement is an essential precondition in any osteoporosis treatment, can correct negative calcium balance in bone absorption and bone formation processes, and is a material basis for improving bone mass. At present, the recommended value of the element calcium taken by middle-aged and elderly people every day is 1000-1500 mg. The calcium agent mainly applied at present comprises calcium carbonate, calcium lactate, calcium citrate, calcium gluconate, active calcium, amino acid chelated calcium and the like. Vitamin D can promote intestinal calcium absorption and urinary calcium reabsorption, participate in calcium and phosphorus regulation, and promote calcium precipitation in bone matrix. Vitamin D may also regulate nerve-muscle tissue coordination. According to the invention, the vitamin D3 and the calcium agent are added into the peony seed oil, so that the anti-osteoporosis activity of the peony seed oil can be further improved, the biomechanical property of bones can be better improved, and the peony seed oil is a health-care food which is suitable for various people to take and can protect bones and prevent osteoporosis. The calcium agent provided by the invention is calcium carbonate, calcium lactate, calcium citrate, calcium gluconate, active calcium and amino acid chelated calcium; the vitamin D provided by the invention is vitamin D2, vitamin D3Calcitriol and alfacalcidol. The best product provided by the invention is composed of peony seed oil, calcium carbonate and vitamin D3The soft capsule is prepared according to the production process of the soft capsule, and each soft capsule contains 1-2 g of peony seed oil and vitamin D34-10 ug, 0.5-1.0 g calcium carbonate.
We also find that the peony seed oil can also form new anti-osteoporosis compound preparations with estrogen medicines, and the compound preparations can be used for preventing and treating female osteoporosis patients after menopause; estrogen deficiency is the leading factor in osteoporosis in postmenopausal women, and therefore, estrogen supplementation can be used to treat osteoporosis. Estrogens natural estrogens and synthetic estrogens. The natural estrogen mainly comprises estradiol and estrone. The artificial synthetic estrogen-like substance comprises diethylstilbestrol, ethinyl estradiol, nilestriol and the like. Estrogens bind to osteoblast receptors to promote bone synthesis and remodeling by promoting the release of various cytokines from osteoblasts, and furthermore, estrogens can directly inhibit the bone resorption action of osteoclasts. However, the side effects of estrogen are related to the dosage used, and the lowest dosage recommended to prevent bone mass loss is not suitable for long-term use. Because estrogen is dangerous to induce coronary heart disease, cerebral apoplexy, breast cancer, thromboembolism and other diseases, FDA only applies it as a preventive drug. NIH also advises the cessation of estrogen therapy for osteoporosis, which is considered more disadvantageous. According to the characteristics of the influence of the peony seed oil on the bone biomechanics and the bone quality, the invention provides that the peony seed oil is combined with low-dose estrogen, so that the side effect generated by the estrogen can be reduced while the osteoporosis is prevented. The medicine composition is especially suitable for preventing bone loss of female postmenopausal osteoporosis patients, and has good prevention and treatment effects on climacteric syndromes accompanied by the patients. The estrogen mentioned in the invention refers to estradiol, estrone, diethylstilbestrol, ethinyl estradiol, nilestriol, tibolone (livee) and primimaline (double meili). The peony seed oil and the low-dose estrogen are used together, which means that the dose of the estrogen contained in each soft capsule is one third to one half of the dose of the existing estrogen preparation. The best product provided by the invention is a soft capsule prepared from peony seed oil and diethylstilbestrol according to a production process of the soft capsule, wherein each soft capsule contains 1-2 g of peony seed oil and 0.05-0.01 mg of diethylstilbestrol.
We also find that the peony seed oil can also form a new compound with an anti-inflammatory drug aspirin, and is used for preventing and treating osteoporosis and bone pain caused by osteoporosis. Our previous studies have demonstrated that aspirin, a cyclooxygenase inhibitor commonly used in the first-class prevention of cardiovascular diseases and cancer, is useful for the first-class prevention of cardiovascular diseases and cancer, and inhibits the synthesis of prostaglandin E2 essential for bone remodeling, has a preventive and therapeutic effect on osteoporosis, and particularly has a superior analgesic effect on pain caused by osteoporosis. This suggests that it may affect the bone health of the user. In vitro studies have shown that aspirin can enhance the survival of bone marrow mesenchymal stem cells (progenitors of osteoblasts) and stimulate differentiation of osteoblasts. Aspirin also inhibits the nuclear factor κ B (NF κ B) pathway and reduces NF receptor activation of expressed κ B ligand, thereby inhibiting osteoclast formation, aspirin may prevent bone loss in an animal model of osteoporosis. Despite the positive impact on bone mineral density, limited human epidemiological studies have shown that aspirin does not reduce the fracture risk. There was a study even mentioning that aspirin increases fracture risk. The current view is that aspirin increases bone mineral density, but its role in fracture prevention is not yet known, and more data is needed to determine the impact of aspirin and bone health on humans. According to the research result of the influence of the peony seed oil on bones, the peony seed oil and aspirin form a compound preparation which can increase bone density, increase ossein, improve the mechanical properties of bones of patients with osteoporosis and prevent fractures. The best product of the compound preparation consists of the peony seed oil and aspirin which are prepared into soft capsules according to the production process of the soft capsules, and each soft capsule contains 1-2 g of the peony seed oil and 100-500 mg of the aspirin.
The following are specific embodiments of the present invention and further description of the technical solutions of the present invention, but the scope of the present invention is not limited to these embodiments, and all changes or equivalent substitutions that do not depart from the spirit of the present invention are included in the scope of the present invention.
Example one
And (3) peony seed oil soft capsules: the peony seed oil which can be used as food or medicine and has the purity meeting the requirement is selected, a proper amount of stabilizing agent, antioxidant, suspending agent and emulsifier are added according to the formula of the soft capsule to prepare the content of the soft capsule, and then the content of each peony seed oil is prepared into 1-2 g according to the production process of the soft capsule.
The peony seed oil can be prepared into hard capsules, tablets, granules, oral liquid or beverages by adding corresponding pharmaceutical excipients according to the requirements of clinical application.
The experimental study on the protective effect of the peony seed oil soft capsule on the bone biomechanical function decline and osteoporosis of the testicle-removed mice: in order to prove that the peony seed oil can replace testosterone to be used for medicines of male osteoporosis patients, a male osteoporosis animal model caused by androgen deficiency is established by a method of taking the testicle, the influence of the testosterone and the peony seed oil on the reduction of the biomechanical property of the mouse bone and the osteoporosis caused by androgen deficiency is observed, and the experimental scheme has the following results:
the experimental scheme of the influence of the peony seed oil soft capsule on the bone of the testicle-removed mouse is as follows: 40 SPF-grade 4-week-old male KM mice were purchased from the center of Experimental animals in Guangdong province, and the license number was SCXK (Guangdong) 2018-. Adaptive feeding for 2 weeks, then evenly dividing into 4 groups according to a random block method, carrying out testicular removal operation at the 6 th week, and beginning intragastric administration of the drug the next day after the operation. Randomized into 4 groups: (1) the sham operation group: sham surgery was performed without removal of the testis. The normal saline for gastric lavage is started two days after the operation; (2) and (3) removing testis: carrying out bilateral testicle extirpation operation on the mouse, reserving epididymis, disinfecting the wound with iodophor every day after the operation is finished until the wound is completely healed, and beginning to perfuse stomach with normal saline two days after the operation; (3) testis-free plus testosterone undecanoate treated group: the operation method is the same as that of the testicle removal group, and the gastric lavage testosterone solution (soybean oil is used as a solvent) of 10.4mg/kg is started two days after the operation; (4) removing testis and adding peony seed oil: the operation method is the same as that of removing the testis group, and peony seed oil is fed three days after the operation; the peony seed oil is taken and administered by intragastric administration according to the concentration of 0.1ml/10 g. Each group of mice was dosed once daily for 8 weeks. In the experiment process, changes of the mice in eating, drinking, activity and the like are observed and recorded every day, the weight is weighed for 1 time in 7 days, and the dosage is adjusted according to the weight change. After the experiment is finished, the left femur is taken, the muscles and the tendons around the femur are removed, the biomechanical indexes of the specimen are detected and analyzed by adopting a Lloyd LR5K Plus bone biomechanical detection system, the experiment adopts a three-point bending method, and the steps are as follows: the left femur of a rat is placed on a testing machine, a pressure head with the diameter of 1mm is used, the loading speed is 2mm/min, the span L is 20mm, the femur is pressurized until fracture occurs, the measurement of a yield point and fracture parameters can be provided, the instrument can record the load (F) and radius (d) change value of each time point in time, a load-displacement curve is drawn, then the maximum load, the fracture load and the elastic load are read, and the rigidity (rigidity coefficient) is calculated. The results of the biomechanical property measurements of the femurs of the experimental mice are shown in table 1.
Table 1: effect of peony seed oil and Testosterone on the biomechanics of debossed mice bone
As can be seen from the results in Table 1, the testicular removal model group compared to the sham operation group, the testicular removal groupBone biomechanicsA decrease in the parameters, in which only the elastic loading is significantly reduced and statistically different (P<0.05）。Testosterone groupCompared with the testicle-removed model group,testosterone groupThe biomechanical parameters of the bone are all increased, wherein the rigidity coefficient is obviously increased and has statistical difference (P<0.01）。Peony seed oil groupThe bone biomechanical parameters were all higher and the maximum load was higher in the testicular-free model group (P<0.05), elastic load: (P<0.01) and a coefficient of rigidity: (P<0.01) all have statistical differences; in comparison to the testosterone group,peony seed oil groupThe breaking load, the maximum load, and the elastic load all increase. In which the elastic load is significantly increased with statistical differences compared to the testosterone group (P<0.01). The fracture load refers to the plastic strain of the bone before fracture, the plasticity of bone materials is reflected, the maximum load reflects the maximum external force born by the bone, the elastic load reflects the maximum deformation length born by the bone in the elastic range, the rigidity coefficient reflects the external hardness of a bone specimen, and the peony seed oil obviously increases the three mechanical properties of the maximum load, the elastic load and the rigidity coefficient of the bone, so that the peony seed oil has an obvious bone strengthening function, wherein the peony seed oil is used for treating bone fractureThe elastic load of the mouse bone is stronger than that of the mouse treated by testosterone, and the fact that the peony seed oil can replace testosterone to prevent the reduction of bone mechanical properties caused by androgen reduction is suggested.
And (3) detecting the peony seed oil and testosterone in the testis-removed mouse thighbone Micro-CT: muscle and attached tissues of the left femur of the mouse are removed, the mouse is placed into a Micro-CT (Micro-computed tomography) instrument, and the metaphysis of the femur is subjected to X-ray scanning. The viva CT40 selects the scan parameters image matrix 2048X 2048, integration time 200ms, energy/intensity 70kVp, 114 μ A, 8W. Scanning is performed with 0 ° rotation. After the scanning is finished, selecting bone tissues 1.0mm away from the far end Of the growth plate and 2.0mm in layer thickness as a cancellous bone interested Region (ROI) for three-dimensional reconstruction, and extracting image information with the lowest threshold value Of 150. Quantitative analysis parameters were analyzed using SCANCO Medical AG software. The parameters are as follows: connection Density (conn.d.), Structural Model Index (SMI), Volume Bone Density (BMD), Bone Volume fraction (Bone Volume/Tissue Volume, BV/TV), Trabecular Number (tb.n), Trabecular Thickness (Trabecular Thickness, tb.th), Trabecular Separation (tb.sp). The results are shown in tables 2 and 3.
TABLE 2 peony seed oil and Testosterone quantitative parameters for Micro-CT (1) ("inx±s,n=10）
From the results in table 2 it can be seen that: (1) compared with the false operation group, the operation table has the advantages that,testicle-removing model groupThe femur connection density and the bone integration number in the Micro-CT parameter are obviously reduced (P<0.01), and the structural model index is significantly increased (P<0.05）。Testosterone groupReduction in femoral coaptation density and bone integration number (P<0.05), structural models rose exponentially with no statistical difference. (2) Compared with the testicle-removed model group, the femur connection density and the bone integration number of the testosterone group are increased (P)<0.05), the structural model index is obviously reduced (P)<0.01). The connection density of peony seed oil group and thighbone,The bone volume fraction increased and the structural model index decreased, all with statistically significant differences.
(3) Compared with the testosterone group, the peony seed oil group has no difference in Micro-CT parameters. The Structural Model Index (SMI) reflects the extent of trabecular (plate-like) and rod-like (rod-like) bone, with SMIs for trabecular and rod-like trabecular bone being 0 and 3 in order. In the case of osteoporosis, the trabecular bone changes from plate-like to rod-like and the SMI value increases. The SMI of the testicular removal model group reaches 3.09, which prompts that the trabecular bone is changed from a plate shape to a rod shape, the osteoporosis appears, and the change of the trabecular bone from the plate shape to the rod shape can be improved by supplementing testosterone or supplementing peony seed oil, so that the loss of the trabecular bone is reduced, the connection density (conn.D) represents the connection number between trabecular bone networks, the connection density of the testicular removal model group is obviously reduced compared with that of a sham operation group, and the reduction of the connection number between the trabecular bone networks of the testicular removed bone can be prevented by supplementing testosterone or supplementing peony seed oil; the bone volume fraction is an important index for evaluating the bone mass, the integral number of the bone parts of the testicle-removed model group is obviously reduced, which indicates that the bone mass is lost in a large amount, and the integral number of the bone parts is obviously increased by taking testosterone or peony seed oil additionally, which indicates that the two medicines can reduce the bone loss but can not reach the level of a control group.
TABLE 3 peony seed oil and Testosterone quantitative parameters for Micro-CT in destestis mice (2) ("Cx±s,n=10）
From the results in table 3, it can be seen that: (1) compared with the false operation group, the operation table has the advantages that,testicle-removing model groupThe number of trabeculae is obviously reduced (P<0.01), the trabecular bone separation degree is obviously increased (P<0.01）。Testosterone treatment groupThe number of trabeculae is obviously reduced (P<0.01), trabecular bone separation increased but no statistical difference. (2) Compared with the testicle-removed model group,testosterone treatment groupThe number and the thickness of the trabeculae are obviously increased, the separation degree of the trabeculae is obviously reduced, and statistics shows thatA significant difference; the peony seed oil has statistically significant differences in the number and thickness of trabeculae, and in the degree of separation of trabeculae. Research results show that the peony seed oil has the same effect as testosterone, can obviously increase the number of trabeculae and the thickness of the trabeculae, reduces the separation degree of the trabeculae and obviously resists the bone loss caused by testicle removal, but compared with a control group, the antagonism cannot reach the level of the control group.
Example two
According to the experimental result of the first embodiment, calcium carbonate and vitamin D3 are added into peony seed oil to form a group of health-care food which is better in curative effect and suitable for being taken by various osteoporosis people. The calcium supplement for peony seed oil can be calcium carbonate, calcium lactate, calcium citrate, calcium gluconate, active calcium, and amino acid chelated calcium; the vitamin D can be vitamin D, vitamin D2Vitamin D3Calcitriol and alfacalcidol. The best product provided by the invention is composed of peony seed oil, calcium carbonate and vitamin D3The components, the formula and the production process are as follows.
Peony seed oil vitamin D calcium preparation soft capsules: selecting peony seed oil which can be used as food or medicine and has purity meeting the requirement, wherein each 1000 peony seeds contain 1 kg-2 kg of peony seed oil and vitamin D34-10 mg of calcium carbonate and 0.5-1.0 kg of calcium carbonate, then adding a proper amount of stabilizing agent, antioxidant, suspending agent and emulsifier to prepare the content of the soft capsule, and then preparing the soft capsule according to the production process of the soft capsule, wherein each soft capsule contains 1-2 g of peony seed oil and vitamin D34-10 ug, 0.5-1.0 g calcium carbonate.
EXAMPLE III
According to the experimental result of the first embodiment, a new anti-osteoporosis compound is formed by adding estrogen medicines into peony seed oil, and the compound preparations can be used for preventing and treating female postmenopausal osteoporosis patients, are particularly suitable for preventing bone loss of the female postmenopausal osteoporosis patients, and have good prevention and treatment effects on climacteric syndromes accompanied by the patients. The estrogen which can be added into the peony seed oil is estradiol, estrone, diethylstilbestrol, ethinyl estradiol, nilestriol, tibolone (liweiai) and primeverine (double meili). The content of each particle of the compound preparation prepared by the peony seed oil and the estrogen is one third to one half of the pharmaceutical preparation of the estrogen. The formula and the production process of the optimal product provided by the invention are as follows:
peony seed oil estrogen soft capsules: selecting peony seed oil which can be used as food or medicine and has the purity meeting the requirement, preparing a soft capsule formula according to the content of 1-2 g of peony seed oil and 0.05-0.01 mg of diethylstilbestrol in each capsule, adding a proper amount of stabilizer, antioxidant, suspending agent and emulsifier to prepare the content of the soft capsule, and preparing the soft capsule according to the production process of the soft capsule.
Example four
According to the experimental result of the first embodiment, a new compound is designed by adding anti-inflammatory aspirin into peony seed oil, and the compound is used for preventing and treating osteoporosis and bone pain caused by osteoporosis. The optimum product formula and the production process of the compound preparation consisting of the peony seed oil and the aspirin are as follows:
peony seed oil aspirin soft capsule: selecting peony seed oil which can be used as food or medicine and has the purity meeting the requirement, blending the formula of the soft capsule according to the content of 1-2 g of peony seed oil and 100-500 mg of aspirin in each capsule, adding a proper amount of stabilizing agent, antioxidant, suspending agent and emulsifier to prepare the content of the soft capsule, and preparing the soft capsule according to the production process of the soft capsule.
Claims (6)
1. The peony seed oil is applied to preparing medicines and health-care foods for preventing and treating low bone biomechanical property and osteoporosis.
2. The application of the peony seed oil in preparing medicines and health-care foods for preventing and treating low bone biomechanical property and osteoporosis of claim 1, wherein the peony seed oil can be prepared into contents of soft capsules by adding a proper amount of a stabilizing agent, an antioxidant, a suspending agent and an emulsifier, and then the contents of the soft capsules are prepared into medicinal preparations containing 1-2 g of peony seed oil per capsule according to the production process of the soft capsules for clinical use.
3. The application of the peony seed oil in preparing medicines and health-care foods for preventing and treating low bone biomechanical property and osteoporosis as claimed in claim 1, wherein the peony seed oil is added with calcium carbonate and vitamin D3, and the formula and preparation method of the peony seed oil vitamin D calcium agent soft capsule are as follows: every 1000 granules contain 1 kg-2 kg of peony seed oil and vitamin D34-10 mg of calcium carbonate and 0.5-1.0 kg of calcium carbonate, then adding a proper amount of stabilizer, antioxidant, suspending agent and emulsifier to prepare the content of the soft capsule, and then preparing the soft capsule according to the production process of the soft capsule, wherein each soft capsule contains 1-2 g of peony seed oil and vitamin D34-10 ug, 0.5-1.0 g calcium carbonate.
4. The application of the peony seed oil in preparing medicines and health-care foods for preventing and treating low bone biomechanical property and osteoporosis as claimed in claim 1, wherein the peony seed oil is added with estrogen drugs, and the formula and the preparation process of the peony seed oil estrogen soft capsule are as follows: blending 1-2 g of peony seed oil and 0.05-0.01 mg of diethylstilbestrol in each capsule, adding a proper amount of a stabilizer, an antioxidant, a suspending agent and an emulsifier to prepare the content of the soft capsule, and preparing the soft capsule according to the production process of the soft capsule.
5. The application of the peony seed oil in preparing medicines and health-care foods for preventing and treating low bone biomechanical property and osteoporosis of the patient according to claim 1, wherein the peony seed oil is added with anti-inflammatory agent aspirin, each peony seed oil contains 1-2 g of peony seed oil and 100-500 mg of aspirin, and then an appropriate amount of stabilizer, antioxidant, suspending agent and emulsifier are added to prepare the content of the soft capsule, and then the soft capsule is prepared according to the production process of the soft capsule.
6. The peony seed oil as claimed in claim 2 to 5 can be used for preparing soft capsules of medicines and health foods for preventing and treating low bone biomechanical property and osteoporosis, and can be added with excipients to prepare clinically applicable hard capsules, tablets, granules, oral liquids and beverages.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911245451.0A CN110876766A (en) | 2019-12-07 | 2019-12-07 | Application of peony seed oil in preparation of medicines and health-care foods for improving biomechanical properties of male bones |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911245451.0A CN110876766A (en) | 2019-12-07 | 2019-12-07 | Application of peony seed oil in preparation of medicines and health-care foods for improving biomechanical properties of male bones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110876766A true CN110876766A (en) | 2020-03-13 |
Family
ID=69730185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911245451.0A Pending CN110876766A (en) | 2019-12-07 | 2019-12-07 | Application of peony seed oil in preparation of medicines and health-care foods for improving biomechanical properties of male bones |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110876766A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111150060A (en) * | 2020-03-31 | 2020-05-15 | 中国农业大学 | Calcium-supplementing and blood-fat-reducing peony seed oil gel oral liquid and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397550A (en) * | 2011-08-30 | 2012-04-04 | 广东医学院 | Medicinal composition composed of aspirin and estrogen and used for preventing and treating osteoporosis |
| CN103190615A (en) * | 2013-04-03 | 2013-07-10 | 上海春芝堂生物制品有限公司 | Liquid calcium soft capsules and preparation method thereof |
| CN107136511A (en) * | 2017-05-25 | 2017-09-08 | 山东省科学院生物研究所 | A kind of peony seed oil composition for promoting cranial nerve development, Peony-seed-oil soft capsule and preparation method thereof |
-
2019
- 2019-12-07 CN CN201911245451.0A patent/CN110876766A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102397550A (en) * | 2011-08-30 | 2012-04-04 | 广东医学院 | Medicinal composition composed of aspirin and estrogen and used for preventing and treating osteoporosis |
| CN103190615A (en) * | 2013-04-03 | 2013-07-10 | 上海春芝堂生物制品有限公司 | Liquid calcium soft capsules and preparation method thereof |
| CN107136511A (en) * | 2017-05-25 | 2017-09-08 | 山东省科学院生物研究所 | A kind of peony seed oil composition for promoting cranial nerve development, Peony-seed-oil soft capsule and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 常雪等: "油料牡丹栽培和籽油加工研究进展", 《安徽农业科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111150060A (en) * | 2020-03-31 | 2020-05-15 | 中国农业大学 | Calcium-supplementing and blood-fat-reducing peony seed oil gel oral liquid and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07507569A (en) | How to promote nitrogen retention in humans | |
| CN1391464A (en) | Formulation for menopausal women | |
| CN109364194A (en) | It maintains bone health and treats the composition of the osteoarthropathy in osteoarthritis and joint | |
| CN110934883A (en) | Naringin preparation for improving male osteoporosis and preventing fracture | |
| CN108783467B (en) | Composition for improving osteoporosis and increasing bone density and preparation method thereof | |
| WO2007091707A1 (en) | Pharmaceutical composition for preventing and/or treating bone disease, functional food, health food, pharmaceutical preparation and tooth root-periodontal tissue formation promoting agent containing the composition | |
| CN110996933A (en) | Agent for preventive and/or supportive therapeutic treatment of parkinson's disease | |
| TWI248359B (en) | Food materials for metabolic bone diseases | |
| CN110876766A (en) | Application of peony seed oil in preparation of medicines and health-care foods for improving biomechanical properties of male bones | |
| AU2012377478B2 (en) | Preparation and method for the prophylaxis and treatment of osteoporosis and bone fractures | |
| CN101401804A (en) | Uses of salvianolic acid B in preparing medicament formulation for preventing and controlling osteoporosis | |
| WO2015001329A1 (en) | Chewable tablet | |
| CN103877140A (en) | Application of saussurea involucrate culture in preparation of product for promoting bone health | |
| CN115944643A (en) | Application of sialic acid in preparing anti-osteoporosis medicine and food | |
| CN113082059A (en) | Composition for preventing and treating osteoporosis and preparation method and application thereof | |
| JPH1112192A (en) | Osteoporosis preventive and treatment agent | |
| JP7232503B2 (en) | Pharmaceutical composition for prevention and/or treatment of bone disease | |
| CN102626420B (en) | Mixed preparation containing strontium, calcium and vitamin D | |
| CN102000110A (en) | Composition used for preventing or treating bone and joint diseases and preparation method thereof | |
| Batool et al. | Exploring Flaxseed's potential in enhancing bone health: Unveiling osteo-protective properties | |
| CN109223771B (en) | Application of brucine A in preparing medicine for preventing and treating osteoporosis | |
| CN109771424B (en) | Pharmaceutical composition for preventing and treating senile type II diabetic osteoporosis and application thereof | |
| CN111991405B (en) | Application of curdione and ginkgoneoic acid in preparation of bone formation promoting medicine | |
| CN1180797C (en) | Medicine for preventing and curing osteoporosis | |
| WO2018222164A2 (en) | Use of an herbal formula containing pumpkin seed oil in bph treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200313 |
|
| WD01 | Invention patent application deemed withdrawn after publication |